{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"138-014-455-074-64X","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"138-014-455-074-64X"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11739,"type":"PATENT","title":"University of Paris Descartes (Paris 5) - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1877,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8379,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* AND Paris Descar*; uni* AND Descar*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1543
Search Applicants and Owners separately: uni* AND Paris Descar*; uni* AND Descar*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1543
a) quantifying, in a tumor tissue sample from said patient, at least one biological marker indicative of the status of the adaptive immune response of said patient against cancer; and\n
b) comparing the value obtained at step a) for said at least one biological marker with a predetermined reference value for the same biological marker; which predetermined reference value is correlated with a specific prognosis of progression of said cancer."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said tumour tissue sample is selected from the group consisting of (i) a global primary tumor (as a whole), (ii) a tissue sample from the center of the tumor, (iii) a tissue sample from the tissue directly surrounding the tumor which tissue may be more specifically named the “invasive margin” of the tumor, (iv) the lymph nodes located at the closest proximity of the tumor, (v) a tumor biopsy performed prior surgery, and (vi) a distant metastasis."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is quantified, at step a), in tumor samples collected from two regions of the tumor, respectively (i) the center of the tumor (CT) and (ii) the invasive margin of the tumor (IM)."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein step a) is selected from the group consisting of:\n
a1) quantifying the said at least one biological marker in a tumor tissue section by immunodetection, separately both (i) in the center of the tumor (CT) and (ii) in the invasive margin (IM); and\n
a2) quantifying the said at least one biological marker in the whole tumor tissue sample by gene expression analysis."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 4, wherein step a1) is performed by quantifying at least two distinct biological markers, separately both (i) in the center of the tumor (CT) and (ii) in the invasive margin (IM)."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 4, wherein step a2) is performed by quantifying at least five distinct biological markers in the whole tissue sample."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker indicative of the status of the adaptive immune response of said patient against cancer consists of at least one biological marker expressed by a cell from the immune system."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker indicative of the status of the adaptive immune response of said patient against cancer consists of at least one biological marker expressed by a cell from the immune system selected from the group consisting of B lymphocytes, T lymphocytes, dendritic cells, NK cells, NKT cells, and NK-DC cells."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is selected from the group consisting of:\n
(i) the number of the density of cells from the immune system contained in the tumor tissue sample and that express the said biological marker, generally a protein marker; and\n
(ii) the expression level of a nucleic acid of interest in the tumor tissue sample, generally the amount of mRNA encoded by a specific gene marker."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker consists of the density of T lymphocytes present at the tumour site."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker consists of the quantification value of a protein expressed by cells from the immune system present at the tumour site."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker consists of the quantification value of the expression of gene specifically expressed by cells from the immune system present at the tumour site."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is selected from the group consisting of CD3, CD8, GZMB, CD45RO, GLNY, TBX21, IRF1, IFNG, CXCL9, CXCL10, CD4, CXCR3, CXCR6, IL-18, IL-18Rbeta, Fractalkine, IL-23, IL-31, IL-15, IL-7, MIG, Perforin, TCRαβ, TCRγδ, LAT, ZAP70, CD5 and CD2."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is selected from the group consisting of the following biological markers:\n
(i) Various biological markers\n
ICAM-2/CD102, 4-1BB/TNFRSF9, IFN-gamma R1, IFN-gamma R2, B7-1/CD80, IL-1 RI, IL-2 R alpha, BLAME/SLAMF8, IL-2 R beta, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, IL-7 R alpha, CCR9, CXCR1/IL-8 RA, CD2, CD3epsilon, CD3zeta, CD3gamma, CD4, CD4+/45RA-, IL-12 R beta 1, CD4+/45RO-, IL-12 R beta 2, CD4+/CD62L-/CD44, CD4+/CD62L+/CD441L-17, CD5, Integrin alpha 4/CD49d, CD6, Integrin alpha E/CD103, CD8, Integrin alpha M/CD11b, CD8+/45RA-, Integrin alpha X/CD11c, CD8+/45RO-, Integrin beta 2/CD18, CD27/TNFRSF7, LAG-3, CD28, LAIR1, CD30/TNFRSF8, LAIR2, CD31/PECAM-1, CD40 Ligand/TNFSF5, NCAM-L1, CD43, NTB-A/SLAMF6, CD45, CD83, CD84/SLAMF5, RANK/TNFRSF11A, L-Selectin, CD229/SLAMF3, SIRP beta 1, CD69, SLAM, Common gamma Chain/IL-2 R gamma, CRACC/SLAMF7, CX3CR1, CXCR3, CXCR4, CXCR6, TNF R1/TNFRSF1A, TNF RII/TNFRSF1B, Fas/TNFRSF6, Fas Ligand/TNFSF6, TSLP, TSLP R, ICAM-1/CD54, IL-2, IFN-gamma, IL-4, IL-5, IL-10, IL-13,\n
(ii) Biological markers of Th1/Th2 cells:\n
Il-2R Common beta Chain, Common gamma Chain/IL-2 R gamma, IFN-gamma, IFN-gamma R1, IL-12, IFN-gamma R2, IL-12 R beta 1, IL-2, IL-12 R beta 2, IL-2 R alpha, IL-2 R beta, IL-24, TNF R1/TNFRSF1A, TNF RII/TNFRSF1B, IL-4 R, TNF-beta/TNFSF1B,\n
(iii) Biological markers of the Interferon family.\n
IFN alpha, IFN beta, IFN-alpha/beta R1, IFN-alpha/beta R, IFN-gamma R1, IFN-gamma R2, IFN-alpha A, IFN-alpha/beta R2, IFN-alpha B2, IFN-beta, IFN-alpha C, IFN-gamma, IFN-alpha D, IFN-alpha G, IFN-omega, IFN-alpha H2,\n
(iv) Biological markers of the Common gamma Chain Receptor Family:\n
Common gamma Chain/IL-2 R gamma, IL-7 R alpha, IL-2, IL-9, IL-2 R alpha, IL-9 R, IL-2 R beta, IL-15, IL-15 R alpha, IL-21, IL-7, IL-21 R, IL-31,\n
(v) Biological markers of the CX3C Chemokines & Receptors:\n
CX3C Chemokine Ligands, CX3CL1/Fractalkine, CX3C Chemokine receptors, CX3CR1,\n
(vi) Biological markers of CXC Chemokines & Receptors,\n
CXC Chemokine Ligands, CXCL13/BLC/BCA-1, CXCL11/I-TAC, CXCL14/BRAK, CXCL8/IL-8, CINC-1, CXCL10/IP-10/CRG-2, CINC-2, CINC-3, CXCL16, CXCL15/Lungkine, CXCL5/ENA, CXCL9/MIG, CXCL6/GCP-2, CXCL7/NAP-2, GRO, CXCL4/PF4, CXCL1/GRO alpha, CXCL12/SDF-1, CXCL2/GRO beta, Thymus Chemokine-1, CXCL3/GRO gamma,\n
CXC Chemokine Receptors, CXCR6, CXCR3, CXCR1/IL-8 RA, CXCR4, CXCR2/IL-8 RB, CXCR5,\n
(vii) Biological markers of CC Chemokines & Receptors,\n
CC Chemokine Ligands, CCL21/6Ckine, CCL12/MCP-5, CCL6/C10, CCL22/MDC, CCL28, CCL3L1/MIP-1 alpha Isoform LD78 beta, CCL27/CTACK, CCL3/MIP-1 alpha, CCL24/Eotaxin-2, CCL4/MIP-1 beta, CCL26/Eotaxin-3, CCL15/MIP-1 delta, CCL11/Eotaxin, CCL9/10/MIP-1 gamma, CCL14a/HCC-1, MIP-2, CCL14b/HCC-3, CCL19/MIP-3 beta, CCL16/HCC-4, CCL20/MIP-3 alpha, CCL1/I-309/TCA-3, CCL23/MPIF-1, MCK-2, CCL18/PARC, CCL2/MCP-1, CCL5/RANTES, CCL8/MCP-2, CCL17/TARC, CCL7/MCP-3/MARC, CCL25/TECK, CCL13/MCP-4CC\n
Chemokine Receptors, CCRI, CCR7, CCR2, CCR8, CCR3, CCR9, CCR4, D6, CCR5, HCR/CRAM-A/B, CCR6\n
(viii) Biological markers of CC Chemokine Inhibitors\n
CCI, CC Viral Chemokine Homologs, MCV-type II, MIP-II, MIP-I, MIP-III\n
(ix) Biological markers of C Chemokines & Receptors\n
The C (gamma) subfamily lacks the first and third cysteine residues. Lymphotactin (also known as SCM-1 alpha) and SCM-1 beta are currently the only two family members. Both have chemotactic activity for lymphocytes and NK cells.\n
C Chemokine Ligands, XCLl/Lymphotactin\n
C Chemokine Receptors, XCR1 and\n
(x) Biological markers of other Interleukins\n
IL-12, IL-12 R beta 1, IL-12 R beta 2, IL-27, IL-15, IL-31"],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is selected from the group consisting of 18s, ACE, ACTB, AGTR1, AGTR2, APC, APOA1, ARF1, AXIN1, BAX, BCL2, BCL2L1, CXCR5, BMP2, BRCA1, BTLA, C3, CASP3, CASP9, CCL1, CCL11, CCL13, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL5, CCL7, CCL8, CCNB1, CCND1, CCNE1, CCR1, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRL2, CD154, CD19, CDla, CD2, CD226, CD244, PDCD1LG1, CD28, CD34, CD36, CD38, CD3E, CD3G, CD3Z, CD4, CD40LG, CD5, CD54, CD6, CD68, CD69, CLIP, CD80, CD83, SLAMF5, CD86, CD8A, CDH1, CDH7, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CEACAM1, COL4A5, CREBBP, CRLF2, CSF1, CSF2, CSF3, CTLA4, CTNNB1, CTSC, CX3CL1, CX3CRI, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CXCR3, CXCR4, CXCR6, CYP1A2, CYP7A1, DCC, DCN, DEFA6, DICER1, DKK1, Dok-1, Dok-2, DOK6, DVL1, E2F4, EBI3, ECE1, ECGF1, EDN1, EGF, EGFR, EIF4E, CD105, ENPEP, ERBB2, EREG, FCGR3A, CGR3B, FN1, FOXP3, FYN, FZD1, GAPD, GLI2, GNLY, GOLPH4, GRB2, GSK3B, GSTP1, GUSB, GZMA, GZMB, GZMH, GZMK, HLA-B, HLA-C, HLA-, MA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA2, HLA-DRA, HLX1, HMOX1, HRAS, HSPB3, HUWE1, ICAM1, ICAM-2, ICOS, ID1, ifnal, ifna17, ifna2, ifna5, ifna6, ifna8, IFNAR1, IFNAR2, IFNG, IFNGR1, IFNGR2, IGF1, IHH, IKBKB, IL10, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA2, IL15, IL15RA, IL17, IL17R, IL17RB, IL18, IL1A, IL1B, IL1R1, IL2, IL21, IL21R, IL23A, IL23R, IL24, IL27, IL2RA, IL2RB, IL2RG, IL3, IL31RA, IL4, IL4RA, IL5, IL6, IL7, IL7RA, IL8, CXCR1, CXCR2, 1L9, IL9R, IRF1, ISGF3G, ITGA4, ITGA7, integrin, alpha E (antigen CD103, human mucosal lymphocyte, antigen 1; alpha polypeptide), Gene hCG33203, ITGB3, JAK2, JAK3, KLRB1, KLRC4, KLRF1, KLRG1, KRAS, LAG3, LAIR2, LEF1, LGALS9, LILRB3, LRP2, LTA, SLAMF3, MADCAM1, MADH3, MADH7, MAF, MAP2K1, MDM2, MICA, MICB, MKI67, MMP12, MMP9, MTA1, MTSS1, MYC, MYD88, MYH6, NCAM1, NFATC1, NKG7, NLK, NOS2A, P2×7, PDCD1, PECAM-, CXCL4, PGK1, PIAS1, PIAS2, PIAS3, PIAS4, PLAT, PML, PP1A, CXCL7, PPP2CA, PRF1, PROM1, PSMB5, PTCH, PTGS2, PTP4A3, PTPN6, PTPRC, RAB23, RAC/RHO, RAC2, RAF, RB1, RBL1, REN, Drosha, SELE, SELL, SELP, SERPINE1, SFRP1, SIRP beta 1, SKI, SLAMFI, SLAMF6, SLAMF7, SLAMF8, SMAD2, SMAD4, SMO, SMOH, SMURF1, SOCS1, SOCS2, SOCS3, SOCS4, SOCS5, SOCS6, SOCS7, SOD1, SOD2, SOD3, SOS1, SOX17, CD43, ST14, STAM, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, STK36, TAP1, TAP2, TBX21, TCF7, TERT, TFRC, TGFA, TGFB1, TGFBR1, TGFBR2, TIMP3, TLRI, TLR10, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TNF, TNFRSF10A, TNFRSF11A, TNFRSF18, TNFRSF1A, TNFRSF1B, OX-40, TNFRSF5, TNFRSF6, TNFRSF7, TNFRSF8, TNFRSF9, TNFSF10, TNFSF6, TOB1, TP53, TSLP, VCAM1, VEGF, WIF1, WNT1, WNT4, XCL1, XCR1, ZAP70 and ZIC2."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker is selected from the group consisting of TNFRSF6B, CEACAM1, PDCD1LG1, CD8A, PTGS2, BIRC5, SELL, INDO, IRAK4, TNF, TNFRSF10A, MMP7, LILRB3, CD3Z, TNFRSF8, GAPD, CXCL10, EBAG9, IL8, STAT1, CXCR3, TGFB1, ICOS, CXCL9, CD97, IL18RAP, CXCR6, ART1, IRF1, B7H3, ACE, IL18R1, TBX21, IL18, PDCD1, IFNG, GNLY, GATA3, VEGF, GZMB, LAT, CD4, IRTA2, IL10, TNFSF4, THSD1 and PDCD1LG2."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The in vitro method according to claim 1, wherein said at least one biological marker consists of a set consisting of the following markers: PDCD1LG1, VEGF, TNFRSF6B, IRF1, IL8RA and SELL."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["A kit for the prognosis of progression of a cancer in a patient, which kit comprises means for quantifying at least one biological marker indicative of the status of the adaptive immune response of said patient against cancer."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A kit for monitoring the effectiveness of treatment (adjuvant or neo-adjuvant) of a subject with an agent, which kit comprises means for quantifying at least one biological marker indicative of the status of the adaptive immune response of said patient against cancer."],"number":19,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}